Forecast

The analysts' average price target is +302,66€ (+3.815,39%). The median is +370,74€ (+4.696,12%).

Buy	9
Hold	3
Sell	0

News Go to news feed

Adicet Bio receives FDA clearance for IND of ADI-212 in metastatic castration-resistant prostate cancer

The FDA has approved the Investigational New Drug (IND) application for ADI-212 from Adicet Bio, a gene‑edited cell therapy targeting prostate-specific membrane antigen (PSMA) that combines a CAR binder with membrane-anchored IL-12 and CRISPR/Cas9-mediated disruption of a Mediator complex subunit. Patient enrollment in the planned phase 1 study is expected to begin in the fourth quarter of 2026. The approval allows Adicet to proceed with human clinical trials and complements the company’s portfolio of allogeneic gamma-delta T-cell therapies and in‑vivo CAR‑T programs. » More on de.investing.com
Adicet Bio expects pivotal lupus data and outlines approval pathway

Adicet Bio plans to publish this quarter what it says is its largest dataset to date for an allogeneic cell therapy in lupus nephritis and SLE (22 patients, 13 with ≥12 months’ follow-up). Lead candidate ADI-001 showed complete B‑cell depletion and a consistent immune reset, with no reports of high‑grade ICANS. Management has held talks with the FDA and intends to publish the agency’s feedback together with the clinical data; single‑arm approval studies of 35–90 patients are under discussion, primarily for lupus nephritis. Adicet emphasizes the practical advantages of the off‑the‑shelf allogeneic approach and sees an initial target market among treatment‑refractory LN patients. » More on de.investing.com
Adicet Bio reports quarterly loss of $2.94 per share and annual loss of $16.95 per share

Adicet Bio reported EPS of -$2.94 per share for the quarter ended December 31, 2025, versus -$5.12 in the year-ago quarter. EPS for the full year was -$16.95 per share, after -$21.28 in the prior year. The report was published on March 12, 2026. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2024, Adicet Bio has already paid 0,0431€ in dividends. The last payout was in September 2024.

Financials

In the last quarter, Adicet Bio had revenue of 0,00€ and net profit of −18,71 Mio€

(EUR)	Jun 2026	YoY
Revenue	0,00	-
Gross profit	0,00	-
Net profit	−18,71 Mio	29,34%
EBITDA	−16,34 Mio	34,84%

Fundamentals

Metric	Value
Market capitalization	+71,80 Mio€
Number of shares	9,35 Mio
52-week high/low	+14,97€ - +5,16€
Dividends	No
Beta	1,59
P/E ratio	−0,78
PEG ratio	−0,01
P/B ratio	+0,80
P/S ratio	0,00

Company profile

Adicet Bio, Inc., ein Biotechnologieunternehmen, entdeckt und entwickelt allogene Gamma-Delta-T-Zelltherapien für Krebs und andere Krankheiten. Das Unternehmen bietet Gamma-Delta-T-Zellen an, die mit chimären Antigenrezeptoren und T-Zell-Rezeptor-ähnlichen Antikörpern ausgestattet sind, um die selektive Tumorbekämpfung zu verbessern, die angeborene und adaptive Anti-Tumor-Immunantwort zu erleichtern und die Persistenz für eine dauerhafte Wirkung bei Patienten zu erhöhen. Das führende Produkt in der Pipeline ist ADI-001, das sich in einer klinischen Studie der Phase I zur Behandlung von Non-Hodgkin-Lymphomen befindet. Das Unternehmen entwickelt außerdem ADI-002, das sich in präklinischen Studien für die Behandlung verschiedener solider Tumore befindet. Adicet Bio, Inc. hat seinen Sitz in Boston, Massachusetts.